Why Does the Novel Coronavirus Spike Protein Interact so Strongly with the Human ACE2? A Thermodynamic Answer.
Jones de AndradePaulo Fernando Bruno GonçalvesPaulo Augusto NetzPublished in: Chembiochem : a European journal of chemical biology (2020)
The SARS-CoV-2 pandemic is the biggest health concern today, but until now there is no treatment. One possible drug target is the receptor binding domain (RBD) of the coronavirus' spike protein, which recognizes the human angiotensin-converting enzyme 2 (hACE2). Our in silico study discusses crucial structural and thermodynamic aspects of the interactions involving RBDs from the SARS-CoV and SARS-CoV-2 with the hACE2. Molecular docking and molecular dynamics simulations explain why the chemical affinity of the new SARS-CoV-2 for hACE2 is much higher than in the case of SARS-CoV, revealing an intricate pattern of hydrogen bonds and hydrophobic interactions and estimating a free energy of binding, which is consistently much more negative in the case of SARS-CoV-2. This work presents a chemical reason for the difficulty in treating the SARS-CoV-2 virus with drugs targeting its spike protein and helps to explain its infectiousness.
Keyphrases
- sars cov
- molecular docking
- molecular dynamics simulations
- respiratory syndrome coronavirus
- angiotensin converting enzyme
- endothelial cells
- binding protein
- angiotensin ii
- healthcare
- public health
- protein protein
- mental health
- small molecule
- risk assessment
- mass spectrometry
- coronavirus disease
- climate change
- drug delivery
- pluripotent stem cells
- social media
- health promotion